Featured Research

from universities, journals, and other organizations

A New Way To Treat Colon Cancer?

Date:
October 11, 2006
Source:
University of Utah Health Sciences Center
Summary:
Researchers at University of Utah's Huntsman Cancer Institute have discovered a new target for possible future colon cancer treatments -- a molecule that is implicated in 85 percent of colon cancer cases.

Researchers at University of Utah's Huntsman Cancer Institute have discovered a new target for possible future colon cancer treatments -- a molecule that is implicated in 85 percent of colon cancer cases.

These findings were published online Oct. 6, 2006, in the Journal of Biological Chemistry.

By knocking out -- that is, genetically disabling -- a molecule called C-Terminal Binding Protein (CTBP) researchers were able to rescue zebrafish from the effects of a mutation in the adenomatous polyposis coli (APC) gene.

In humans, mutations in this gene long have been known to initiate a series of events that cause colon polyps, which eventually become cancerous. APC mutations play a role in 85 percent of colon cancers. The new findings mean CTBP also is involved in that proportion of colon cancers.

In zebrafish, APC mutations keep the intestine from developing properly. "In essence, knocking out CTPB promotes normal development of the intestine in zebrafish carrying an APC mutation," says David A. Jones, a University of Utah associate professor of oncological sciences and leader of the study.

In normal cells of both humans and zebrafish, the APC gene controls the amount of CTBP present by marking it for destruction. In tumor cells with mutated APC, CTPB is not destroyed; instead it accumulates in the cell.

One function of CTBP is to turn off the process that converts vitamin A into retinoic acid in the cell. Retinoic acid is essential in cell differentiation -- the function that determines what type of cell forms and how long it lives. This study observed that in both zebrafish and human tissues with APC mutations, there are high CTBP levels and low capability to produce retinoic acid. In APC-mutated tissues in which CTBP had been "knocked out," retinoic acid production was restored.

Earlier studies in Jones' lab showed that lack of retinoic acid caused zebrafish intestines to form incorrectly, and that adding retinoic acid corrected the problems.

"Knocking out CTBP does exactly the same thing, and the logical conclusion is that it's because CTBP controls retinoic acid production," says Jones. "Since CTBP is a completely new target, we must now look for potential chemical agents that would work to block its actions. That could take three to five years."

Other Huntsman Cancer Institute researchers participating in this study include Lincoln D. Nadauld, Reid Phelps, Brent C. Moore, Annie Eisinger, Imelda T. Sandoval, Stephanie Chidester, Peter W. Peterson, Elizabeth J. Manos, Bradford Sklow, and Randall W. Burt.

Funding for this study was provided by the National Cancer Institute and the Huntsman Cancer Foundation.

About colorectal cancer

Colorectal cancer is the second leading cause of cancer deaths in the United States. In 2006, the American Cancer Society estimates that 106,680 cases of colorectal cancer will be diagnosed in the nation, with 700 cases in Utah. Colorectal cancer is the third most common cancer in the United States and Utah.

About Huntsman Cancer Institute

Huntsman Cancer Institute's mission is to understand cancer from its beginnings, to use that knowledge in the creation and improvement of cancer treatments, to relieve the suffering of cancer patients, and to provide education about cancer risk, prevention, and care. HCI is a National Cancer Institute-designated cancer center, which means that it meets the highest national standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network, a nonprofit alliance of the world's leading cancer centers, dedicated to improving the quality and effectiveness of care provided to patients with cancer.


Story Source:

The above story is based on materials provided by University of Utah Health Sciences Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Utah Health Sciences Center. "A New Way To Treat Colon Cancer?." ScienceDaily. ScienceDaily, 11 October 2006. <www.sciencedaily.com/releases/2006/10/061010022431.htm>.
University of Utah Health Sciences Center. (2006, October 11). A New Way To Treat Colon Cancer?. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2006/10/061010022431.htm
University of Utah Health Sciences Center. "A New Way To Treat Colon Cancer?." ScienceDaily. www.sciencedaily.com/releases/2006/10/061010022431.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins